Hepatitis B virus infection and alcohol consumption

被引:60
作者
Iida-Ueno, Ayako [1 ]
Enomoto, Masaru [1 ]
Tamori, Akihiro [1 ]
Kawada, Norifumi [1 ]
机构
[1] Osaka City Univ, Grad Sch Med, Dept Hepatol, Osaka 5458585, Japan
关键词
Entecavir; Genetic factors; Hepatocellular carcinoma; Interferon; HEPATOCELLULAR-CARCINOMA; LIVER-DISEASE; C VIRUS; OXIDATIVE STRESS; INTERFERON THERAPY; ETHNIC-DIFFERENCES; CIGARETTE-SMOKING; GENE-EXPRESSION; NATURAL-HISTORY; RISK;
D O I
10.3748/wjg.v23.i15.2651
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and the second most common cause of cancer deaths worldwide. The top three causes of HCC are hepatitis B virus (HBV), hepatitis C virus (HCV), and alcoholic liver disease. Owing to recent advances in direct-acting antiviral agents, HCV can now be eradicated in almost all patients. HBV infection and alcoholic liver disease are expected, therefore, to become the leading causes of HCC in the future. However, the association between alcohol consumption and chronic hepatitis B in the progression of liver disease is less well understood than with chronic hepatitis C. The mechanisms underlying the complex interaction between HBV and alcohol are not fully understood, and enhanced viral replication, increased oxidative stress and a weakened immune response could each play an important role in the development of HCC. It remains controversial whether HBV and alcohol synergistically increase the incidence of HCC. Herein, we review the currently available literature regarding the interaction of HBV infection and alcohol consumption on disease progression.
引用
收藏
页码:2651 / 2659
页数:9
相关论文
共 61 条
[1]   Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives [J].
Asselah, Tarik ;
Boyer, Nathalie ;
Saadoun, David ;
Martinot-Peignoux, Michele ;
Marcellin, Patrick .
LIVER INTERNATIONAL, 2016, 36 :47-57
[2]   Factors That Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-Alfa [J].
Buster, Erik H. C. J. ;
Hansen, Bettina E. ;
Lau, George K. K. ;
Piratvisuth, Teerha ;
Zeuzem, Stefan ;
Steyerberg, Ewout W. ;
Janssen, Harry L. A. .
GASTROENTEROLOGY, 2009, 137 (06) :2002-2009
[3]   The-159C/T polymorphism in the promoter region of the CD14 gene is associated with advanced liver disease and higher serum levels of acute-phase proteins in heavy drinkers [J].
Campos, J ;
Gonzalez-Quintela, A ;
Quinteiro, C ;
Gude, F ;
Perez, LF ;
Torre, JA ;
Vidal, C .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2005, 29 (07) :1206-1213
[4]   Natural history of chronic hepatitis B REVEALed [J].
Chen, Chien-Jen ;
Yang, Hwai-I .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 (04) :628-638
[5]   Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].
Chen, CJ ;
Yang, HI ;
Su, J ;
Jen, CL ;
You, SL ;
Lu, SN ;
Huang, GT ;
Iloeje, UH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73
[6]   Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naive patients with chronic hepatitis B infection [J].
Chung, Won Gil ;
Kim, Hong Joo ;
Choe, Young Gil ;
Seok, Hyo Sun ;
Chon, Chang Wook ;
Cho, Yong Kyun ;
Kim, Byung Ik ;
Koh, Young Yool .
CLINICAL AND MOLECULAR HEPATOLOGY, 2012, 18 (02) :195-202
[7]   Oxidative stress inhibits IFN-α-induced antiviral gene expression by blocking the JAK-STAT pathway [J].
Di Bona, Danilo ;
Cippitelli, Marco ;
Fionda, Cinzia ;
Camma, Calogero ;
Licata, Anna ;
Santoni, Angela ;
Craxi, Antonio .
JOURNAL OF HEPATOLOGY, 2006, 45 (02) :271-279
[8]   Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women [J].
Donato, F ;
Tagger, A ;
Gelatti, U ;
Parrinello, G ;
Boffetta, P ;
Albertini, A ;
Decarli, A ;
Trevisi, P ;
Ribero, ML ;
Martelli, C ;
Porru, S ;
Nardi, G .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 155 (04) :323-331
[9]  
Enomoto M, 2006, CLIN LAB, V52, P43
[10]  
European Medicines Agency, 2010, EMEA/CHMP/EWP/20097/2008